15.05.2019 • News

Bionure Appoints Lucia Septien as Chief Medical Officer

Bionure has appointed Lucia Septien as chief medical officer. Source: Bionure
Bionure has appointed Lucia Septien as chief medical officer. Source: Bionure

Bionure, a Barcelona, Spain-based clinical stage R&D company specialized in the treatment of neurodegenerative diseases, has appointed Lucia Septien as chief medical officer (CMO).

Septien joins Bionure from DBV Technologies where she also held the CMO position. Prior to that, she worked as a clinical doctor in neurology and psychiatry and then held diverse roles at major pharmaceutical companies, including Pfizer, Wyeth, GSK, Servier and Ipsen.

"We warmly welcome Lucia to Bionure. With her sensitivity for patients, her solid experience in CNS drug development and her leadership skills, she will strengthen our team," said Laurent Nguyen, CEO of Bionure. “We are convinced of her ability to successfully implement our neuroprotection projects.”

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

From Catalogue to Collaboration

Enamine's Expert Insights Collection Is Free to Download
Enamine’s 35 Years of Advancing Drug Discovery

Enamine's Expert Insights Collection Is Free to Download

From catalogue to collaboration — explore 35 years of drug discovery breakthroughs, novel building blocks, and the science shaping tomorrow's medicines. Download your complimentary copy now.

most read